Phase III Trial Shows Hypofractionated Radiotherapy Plus Chemotherapy Matches Survival Rates and Reduces Toxicity Compared to Conventional Treatment in Limited-Stage SCLC
(Barcelona, Spain — September 8, 2025) — A pivotal multi-center, randomized phase III clinical trial has recently demonstrated that a ...
